About NIH
The National Institute of Health is a government agency
leading public health and medical research in South Korea
About NIH
Browse the latest research papers,
patents, and technological achievements
About NIH
Recent news from the National Institute of Health
2026 Second Official Announcement: International Collaborative Research on Tuberculosis
Update 01.10.2026
KNIH (Korea National Institute of Health)
- 2026 Grant Program
Official Announcement on International Collaborative Research for Tuberculosis
(Sponsored by the Korea National Institute of Health)
1. Background and Rationale
The Korea National Institute of Health (KNIH) supports the development and global implementation of diagnostic technologies that contribute to achieving the goals of the End TB Strategy. To facilitate the rapid diagnosis of drug-resistant TB, the World Health Organization (WHO) recognizes targeted next-generation sequencing (tNGS) as a class of technologies capable of rapidly detecting resistance-associated mutations across a broad range of anti-TB drugs, including new drugs such as bedaquiline (BDQ) and delamanid (DLM). Consistent with WHO recommendations, this program aims to generate evidence on the clinical utility of a tNGS-based diagnostic technology and support its further development and future implementation in clinical settings through international collaborative research.
The proposed research will evaluate the diagnostic performance of a KNIH-led prototype tNGS diagnostic kit for detecting mutations associated with resistance to anti-TB drugs in clinical settings in countries with a high TB burden.
In parallel, MDR-TB isolates obtained from participating countries will undergo phenotypic drug susceptibility testing, including minimum inhibitory concentration testing, and whole-genome sequencing to characterize their phenotypic and genotypic drug-resistance profiles, including resistance to new anti-TB drugs. These profiles will be evaluated for their associations with treatment outcomes.
Through this international collaborative research, the proposed study aims systematically demonstrate the clinical utility of the tNGS-based rapid diagnostic technology through international collaborative research, and to investigate the associations of the genotypic and phenotypic drug-resistance profiles of MDR-TB isolates with treatment outcomes. Ultimately, the study seeks to generate robust scientific evidence through international collaboration to support the early diagnosis of MDR-TB, inform treatment decision-making.
2. Project Details
2.1. Title
Evaluation of the clinical utility of a tNGS-based diagnostic technology for antituberculosis drug resistance and Its treatment associations to support field implementation
2.2. Project period
Within 36 months from the contract date:
1. Year 1: Agreement date (2026) - October 31, 2027
2. Year 2: November 1, 2027 - October 31, 2028
3. Year 3: November 1, 2028 - October 31, 2029
The actual start date and annual budget periods will be specified in the final agreement.
2.3. Estimated Funding
The year 1 fund will be approximately 297,400 USD (400,000,000 KRW).
The year 2 fund will be approximately 272,000 USD (366,000,000 KRW).
The year 3 fund will be approximately 272,000 USD (366,000,000 KRW).
Funding amounts are estimates and may be adjusted based on the final scope of work, budget review, availability of funds, and terms of the agreement.
2.4 Eligible Countries
Applications will be accepted from institutions located in countries with a high TB burden, defined for this funding opportunity as countries with an estimated TB incidence exceeding 100 cases per 100,000 population.
2.5. Eligibility of the Principal Investigator
The proposed Principal Investigator must hold an M.D., Ph.D., or equivalent doctoral degree and possess relevant expertise in TB diagnostics, clinical research, microbiology, molecular epidemiology, or a related field.
Applicant institutions must demonstrate the infrastructure and technical capacity necessary to conduct the proposed research, including access to appropriate clinical specimens, mycobacterial culture and drug-susceptibility testing facilities, sequencing capacity, and applicable ethical and regulatory oversight.
3. Research Objectives and Scope
3.1. Objective
The objectives of this funding opportunity are to:
1. Conduct a multisite performance evaluation of a KNIH-led prototype tNGS diagnostic kit for MDR-TB; and
2. Perform a comparative analysis of the phenotyptic and genotypic characteristics of MDR-TB isolates obtained from clinical specimens and assess their associations with treatment outcomes
3.2. Project I: Evaluation of the tNGS Prototype and Bioinformatics System
KNIH provides the prototype tNGS-based kit, testing protocol, bioinformatics software, and data-analysis protocol.
Phase I: Performance evaluation of the tNGS diagnostic kit using M. tuberculosis isolates
The recipient institution will be expected to perform the following activities:
1. Identify and provide access to a minimum of:
• 50 drug-susceptible M. tuberculosis isolates;
• 50 rifampicin-monoresistant isolates;
• 50 isoniazid-monoresistant isolates;
• 200 MDR-TB isolates; and
• 50 BDQ-resistant isolates.
2. Provide the results of mycobacterial culture, phenotypic drug-susceptibility testing (pDST), Xpert testing, and other relevant routine diagnostic tests performed in accordance with applicable national standards and laboratory guidelines.
3. Perform library preparation, sequencing, and analysis using the tNGS assay on an Illumina sequencing platform.
4. Conduct a structured user evaluation of the bioinformatics analysis system, including its usability, workflow, and interpretation functions.
5. Share sequencing data, analysis results, test-performance data, and user-evaluation findings with KNIH in accordance with the approved study protocol and data-sharing agreement.
Phase II: Performance Evaluation Using Clinical specimen
The recipient institution will be expected to perform the following activities:
1. Establish a multisite clinical research network capable of recruiting participants and collecting, processing, and testing sputum specimens.
2. Enroll or obtain eligible specimens from at least:
• 100 patients with drug-susceptible TB; and
• 200 patients with MDR-TB, including at least 50 patients with BDQ-TB.
(e.g., 100 patients in Year 2 and 200 patients in Year 3 as annual totals)
* Patients with suspected TB aged 15 years or older are eligible for enrollment, including HIV-positive patients and both new and previously treated (retreatment) patients.
3. Provide results from mycobacterial culture, pDST, Xpert testing, and other relevant molecular or microbiological tests performed in accordance with applicable national standards and laboratory guidelines.
4. Perform library preparation, sequencing, and analysis using the tNGS assay on an Illumina sequencing platform.
5. Conduct a structured user evaluation of the bioinformatics analysis system and share the resulting data and findings.
6. Diagnostic performance will be evaluated in terms of sensitivity, specificity, positive predictive value, negative predictive value, and positive and negative likelihood ratios, using culture and Xpert as reference standards.
For detection of M. tuberculosis, culture and/or a validated molecular test may be used as the reference standard. For drug-resistance detection, pDST and an appropriate composite or sequencing-based reference standard should be used, depending on the drug and resistance mechanism evaluated.
3.3 Project II: Characterization of M. tuberculosis Isolates from the MDR-END Plus Trial
This component will characterize the drug-resistance and molecular features of MDR-TB isolates linked to the MDR-END Plus trial and evaluate their associations with treatment outcomes.
The recipient institution will be expected to perform the following activities:
1. Identify and secure BDQ-resistant isolates linked to participants in the MDR-END Plus trial.
2. Determine MICs for first- and second-line anti-TB drugs, including rifampicin and isoniazid, using Sensititre™ MIC plates or another validated method.
3. Determine MICs across extended concentration ranges for newer anti-TB drugs, including BDQ and DLM, using customized Sensititre™ MIC plates or another validated method.
4. Perform whole-genome sequencing (WGS) to characterize resistance-associated mutations, strain lineages, transmission-related features, and other relevant molecular epidemiological characteristics.
5. Compare phenotypic susceptibility, MIC, and genomic findings and evaluate their associations with treatment outcomes.
6. Share relevant laboratory, genomic, and clinical outcome data in accordance with the approved protocol, informed-consent provisions, and applicable data-sharing agreements.
3.4 Sample Collection, Storage, and Data Management
1. Sample collection and processing will be performed in accordance with the standard operating procedures of the research performing institutions.
2. Samples will be stored in a designated central biobank in the host country.
3. The transfer and sharing of samples and data will comply with the ethical and legal regulatory requirements of both countries (with separate consent forms, including consent for the provision of samples and TB-derived DNA).
4. Coded (pseudonymized) identifiers used for personal data protection.
3.5 Ethical Considerations
1. Obtaining IRB approval.
2. Securing written informed consent from study participants.
4. Affiliation
Government institute, university, hospital, etc.
5. Reporting System
The application should be submitted in English via email before October 5, 2026.
Please use MS Word format (important).
6. Key Dates
- Application opens on October 1, 2026
- Application due by October 5, 2026
* The letter of intent and project proposal should be submitted via email (sem21c@korea.kr)
Confirmation of your submission will be sent via email within one day.
- Review will be completed by October 21, 2026
- Result notification (via email) October 26, 2026
7. Contact
sem21c@korea.kr
(28159)
187, Osongsaengmyeong2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Division of Bacterial Disease Research, Center for Infectious Disease Research, Korea National Institute of Disease, National Institute of Health, South Korea
TEL: +82-43-719-8462